Specialist Updates 
Cardiology

Icosapent ethyl associated with plaque regression

Small trial shows regression of several plaque components, authors report
Medicom Staff writer
0
3 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Taking icosapent ethyl daily in addition to a statin and following a low cholesterol diet may lead to regression of atherosclerotic plaque, a small trial shows.

In the EVAPORATE trial, reported at the European Society of Cardiology’s virtual congress (ESC 2020) this week, 80 people with manifest coronary atherosclerosis were randomised to either 4g of icosapent ethyl or placebo daily.

All participants had at least one angiographic coronary stenosis with a minimum of 20% narrowing seen on multidetector CT, were on a statin and had persistently elevated triglyceride levels (median 2.93mmol/L).

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .